International conference to present, learn and discuss Pharmacometric Science and Applications. Official language is English.
January 30(Wed) & 31(Thu), 2019Program now preparing...
Keio University Mita Campus, North Building Conference Hall.
Address: 2-15-45 Mita, Minato-ku, Tokyo 108-8345, Japan.
Admission fee is free, but advanced registration is required.
Please click the 'Registration' button to entry.
January 21(Mon), 2019
Keio University, in support of Japan Science and Technology Agency (JST), and with auspices of International Society of Pharmacometrics (ISoP) and Japan Pharmaceutical Manufacturers Association (JPMA).
Professor Yusuke Tanigawara,Ph.D.
Keio University School of Medicine
ISoP President 2016-2017 (Institut Roche, France)
‘Tumor Growth Inhibition-Overall Survival Modeling and Simulation for Immunotherapies: A Case Study with Atezolizumab.’
Jin Yan Jin
ISoP President 2017-2018 (Genentech, U.S.A.)
‘Challenges and Opportunities of Quantitative Pharmacology in Biologics Development.’
‘Overview of draft regulatory guideline on exposure-response analysis’
Shanghai University of Chinese Medicine, China
‘PK/PD model informed drug clinical development in our practice’
The Catholic University of Korea, South Korea
‘Development of an open PBPK software (DAllPhin) for human PK prediction’
Seoul National University and Hospital, South Korea
‘Application of pharmacometrics for optimized drug development and personalized pharmacotherapy’
National Cheng Kung University, Taiwan
‘Pharmacokinetics and pharmacodynamics of vancomycin in patients with Enterococcal bacteremia’
University of Oxford and Mahidol University, Thailand
‘Pharmacokinetic and pharmacodynamic modelling of antimalarial drugs’
International Medical University in Kuala Lumpur, Malaysia
‘Current status of research and education of pharmacometrics in Malaysia’
Siti Maisharah Sheikh Ghadzi
Universiti Sains Malaysia, Malaysia
‘Pharmacometrics time-to-event modelling of recurrent stroke among patients with type 2 diabetes mellitus’
Mayu Osawa (Bristol-Myers Squibb)
‘Benefit-risk assessment of nivolumab flat dose relative to weight-based dosing regimen’
Keizo Fukushima (Kobe Gauin University)
‘PopPKPD analysis of cisplatin induced nephrotoxicity: an apoptotic signal transduction-indirect response model’
Takaaki Yamada (Kyushu University Hospital)
‘Population pharmacokinetics of teicoplanin in neonates and children’
Shinichi Tsuchiwata (Pfizer)
‘A Markov transition model for characterization of exposure–response of tofacitinib during maintenance therapy in patients with ulcerative colitis’
Tomohiro Sasaki (Otsuka Pharmaceutical)
‘Preclinical PK/PD model-based human dose selection for anti-tumor drug OPC-X’
Chihiro Hasegawa (Ono Pharmaceutical)
‘Simplification of multi-scale systems models for data-driven analyses’
Hidefumi Kasai (Keio University)
‘Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid’
Takanori Ogawa (Certara)
‘Comparison of life span model and transit compartment model to model real clinical data’
Kazuro Ikawa (Hiroshima University)
‘Pharmacometric approach to optimize antibacterial regimens for drug-resistant infections’
Ken-ichi Sako (Nihon Pharmaceutical University)
‘Population pharmacokinetic analysis of vancomycin in adult cancer patients’